Finch Therapeutics Group, Inc. (FNCH) 

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Finch Therapeutics Group, Inc. ("Finch” or the "Company") (NASDAQ: FNCH). Investors who purchased Finch securities are encouraged to obtain additional information and assist the investigation.

 

The investigation concerns whether Finch and certain of its officers and/or directors have violated federal securities laws.

 

On or around March 19, 2021, Finch conducted its initial public offering (“IPO”), selling 7.5 million shares priced at $17.00.  Then, on March 1, 2022, Finch issued a press release “announc[ing] that it has paused enrollment in PRISM4, its Phase 3 clinical trial of CP101 in recurrent C. difficile infection (CDI) following receipt of a clinical hold letter from the U.S. Food and Drug Administration (FDA) on February 24, 2022, requesting additional information about Finch’s SARS-CoV-2 donor screening protocols.”  Finch reported that “[f]ollowing communications with FDA in January 2022, on February 24, 2022, the FDA sent a letter stating that it needs additional information about Finch’s SARS-CoV-2 screening protocols and that a clinical hold remains in effect until the FDA’s requests have been satisfactorily addressed.”  On this news, Finch’s stock price fell sharply during intraday trading on March 2, 2022.

 

If you are aware of any facts relating to this investigation or purchased Finch shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.